34
Participants
Start Date
April 30, 2008
Primary Completion Date
November 30, 2009
Study Completion Date
November 30, 2009
Insulin Glargine (LANTUS)
Subcutaneous insulin glargine was initiated 90 prior to the insulin glulisine infusion discontinuation (i.e. 48 hours after randomization) and titrated as per physician preference to maintain the plasma glucose between 90-130 mg/dL
Insulin Glulisine (Apidra)
"Prior PCI, subjects received a single IV bolus of insulin glulisine. The dose was 0.025 U/kg based upon patient reported weight.~Then IV insulin glulisine infusion was started within one hour of the IV insulin glulisine bolus and administered at a minimum rate of 2 U/h for 48 hours. The infusion was titrated in order to achieve and maintain the plasma glucose between 90 and 130 mg/dL."
Standard Therapy
Standard insulin therapy titrated to blood sugar control
Sanofi-Aventis Administrative Office, Bridgewater
Sanofi-Aventis Administrative Office, Buenos Aires
Sanofi-Aventis Administrative Office, São Paulo
Sanofi-Aventis Administrative Office, Laval
Sanofi-Aventis Administrative Office, Col. Coyoacan
Lead Sponsor
Sanofi
INDUSTRY